An international phase 3 clinical trial that treated patients with high-risk localized and locally advanced prostate cancer with apalutamide—a next-generation neoadjuvant androgen-receptor pathway inhibitor (ARPI)—plus hormone ...
11 hours ago
0
3
Adding darolutamide to standard treatment for aggressive prostate cancer reduced the risk of the disease spreading in an international phase 3 trial.
13 hours ago
0
7
Adding abiraterone to standard treatment provides a lasting survival benefit for men whose prostate cancer has already spread at diagnosis, reinforcing the value of early treatment intensification. The findings come from ...
19 hours ago
0
3
Findings from STAMINA, the largest trial of its kind, published in The Lancet Oncology, show that a purpose-designed lifestyle program offering structured exercise, dietary advice and behavioral support as part of routine ...
Sep 7, 2026
0
73
Men with prostate cancer have a high risk of heart disease, especially when treated with hormone therapy. A large international, first-of-its-kind study led by Hamilton researchers found that routine referrals to an internist ...
Aug 30, 2026
0
415
Earlier use of a targeted radionuclide therapy delays metastatic prostate cancer progression when administered as part of a trio of drugs, according to a Phase III clinical trial led by Weill Cornell Medicine, NewYork-Presbyterian, ...
Aug 7, 2026
0
169
High-risk localized and locally advanced prostate cancer patients treated with apalutamide—a next generation neoadjuvant androgen-receptor pathway inhibitor (ARPI)—plus hormone therapy before and after prostate cancer surgery ...
Jun 1, 2026
0
3
Researchers at Columbia University Irving Medical Center have identified a gene that drives the development of neuroendocrine prostate cancer (NEPC), an aggressive form of the disease. The study published in the Journal of ...
May 28, 2026
0
6
A new blood test could help doctors identify whether a treatment for advanced prostate cancer is failing weeks earlier than current tests, according to a U.K.-wide study led by UCL researchers. The study, published in Nature ...
May 18, 2026
0
37
The FOXA1 protein is a potentially highly sensitive diagnostic marker for small cell carcinoma of the prostate and possibly other aggressive prostate cancer subtypes that are difficult to diagnose due to a loss of traditional ...
May 14, 2026
0
6
